Serglycin: A structural and functional chameleon with wide impact on immune cells

Journal of Immunology

Volumn 187, Issue 10, 2011, Pages 4927-4933

  Kolset, Svein O ^a   Pejler, Gunnar ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLYCOSAMINOGLYCAN; GLYPICAN; GRANZYME B; HEPARIN; HERMES ANTIGEN; MESSENGER RNA; PROTEOGLYCAN; SERGLYCIN; SYNDECAN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; BLOOD CLOTTING; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; EOSINOPHIL; GLYCOSYLATION; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MYELOMA CELL; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; SHORT SURVEY;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM; PROTEOGLYCANS; SECRETORY VESICLES; STRUCTURE-ACTIVITY RELATIONSHIP; VESICULAR TRANSPORT PROTEINS;

EID: 81455131876     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100806     Document Type: Short Survey

References (63)

1. Bishop, J. R., M. Schuksz, and J. D. Esko. 2007. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446: 1030-1037. (Pubitemid 46676065)
2. Horner, A. A. 1971. Macromolecular heparin from rat skin. Isolation, characterization, and depolymerization with ascorbate. J. Biol. Chem. 246: 231-239.
3. Yurt, R. W., R. W. Leid, Jr., and K. F. Austen. 1977. Native heparin from rat peritoneal mast cells. J. Biol. Chem. 252: 518-521. (Pubitemid 8065326)
4. Yurt, R. W., R. W. Leid, Jr., J. Spragg, and K. F. Austen. 1977. Immunologic release of heparin from purified rat peritoneal mast cells. J. Immunol. 118: 1201-1207. (Pubitemid 8085510)
5. Robinson, H. C., A. A. Horner, M. Höök, S. Ogren, and U. Lindahl. 1978. A proteoglycan form of heparin and its degradation to single-chain molecules. J. Biol. Chem. 253: 6687-6693. (Pubitemid 9060480)
6. Bourdon, M. A., A. Oldberg, M. Pierschbacher, and E. Ruoslahti. 1985. Molecular cloning and sequence analysis of a chondroitin sulfate proteoglycan cDNA. Proc. Natl. Acad. Sci. USA 82: 1321-1325. (Pubitemid 15111044)
7. Tantravahi, R. V., R. L. Stevens, K. F. Austen, and J. H. Weis. 1986. A single gene in mast cells encodes the core peptides of heparin and chondroitin sulfate proteoglycans. Proc. Natl. Acad. Sci. USA 83: 9207-9210. (Pubitemid 17223564)
8. Bourdon, M. A., T. Krusius, S. Campbell, N. B. Schwartz, and E. Ruoslahti. 1987. Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. Proc. Natl. Acad. Sci. USA 84: 3194-3198. (Pubitemid 17085371)
9. Bourdon, M. A., M. Shiga, and E. Ruoslahti. 1986. Identification from cDNA of the precursor form of a chondroitin sulfate proteoglycan core protein. J. Biol. Chem. 261: 12534-12537. (Pubitemid 17204201)
10. Kjellén, L., I. Pettersson, P. Lillhager, M. L. Steen, U. Pettersson, P. Lehtonen, T. Karlsson, E. Ruoslahti, and L. Hellman. 1989. Primary structure of a mouse mastocytoma proteoglycan core protein. Biochem. J. 263: 105-113. (Pubitemid 19243821)
11. Stevens, R. L., K. Otsu, and K. F. Austen. 1985. Purification and analysis of the core protein of the protease-resistant intracellular chondroitin sulfate E proteoglycan from the interleukin 3-dependent mouse mast cell. J. Biol. Chem. 260: 14194-14200. (Pubitemid 16197488)
12. Uhlin-Hansen, L., T. Wik, L. Kjellén, E. Berg, F. Forsdahl, and S. O. Kolset. 1993. Proteoglycan metabolism in normal and inflammatory human macrophages. Blood 82: 2880-2889. (Pubitemid 23318097)
13. Oynebråten, I., B. Hansen, B. Smedsrød, and L. Uhlin-Hansen. 2000. Serglycin secreted by leukocytes is efficiently eliminated from the circulation by sinusoidal scavenger endothelial cells in the liver. J. Leukoc. Biol. 67: 183-188.
14. Åbrink, M., M. Grujic, and G. Pejler. 2004. Serglycin is essential for maturation of mast cell secretory granule. J. Biol. Chem. 279: 40897-40905. (Pubitemid 39287689)
15. Ringvall, M., E. Rönnberg, S. Wernersson, A. Duelli, F. Henningsson, M. Abrink, G. García-Faroldi, I. Fajardo, and G. Pejler. 2008. Serotonin and histamine storage in mast cell secretory granules is dependent on serglycin proteoglycan. J. Allergy Clin. Immunol. 121: 1020-1026.
16. Melo, F. R., I. Waern, E. Rönnberg, M. Åbrink, D. M. Lee, S. M. Schlenner, T. B. Feyerabend, H. R. Rodewald, B. Turk, S. Wernersson, and G. Pejler. 2011. A role for serglycin proteoglycan in mast cell apoptosis induced by a secretory granulemediated pathway. J. Biol. Chem. 286: 5423-5433.
17. Braga, T., M. Grujic, A. Lukinius, L. Hellman, M. Abrink, and G. Pejler. 2007. Serglycin proteoglycan is required for secretory granule integrity in mucosal mast cells. Biochem. J. 403: 49-57. (Pubitemid 46569866)
18. Grujic, M., T. Braga, A. Lukinius, M. L. Eloranta, S. D. Knight, G. Pejler, and M. Abrink. 2005. Serglycin-deficient cytotoxic T lymphocytes display defective secretory granule maturation and granzyme B storage. J. Biol. Chem. 280: 33411-33418. (Pubitemid 41397139)
19. Metkar, S. S., B. Wang, M. Aguilar-Santelises, S. M. Raja, L. Uhlin-Hansen, E. Podack, J. A. Trapani, and C. J. Froelich. 2002. Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation. Immunity 16: 417-428. (Pubitemid 34260919)
20. Grujic, M., J. P. Christensen, M. R. Sørensen, M. Abrink, G. Pejler, and A. R. Thomsen. 2008. Delayed contraction of the CD8+ T cell response toward lymphocytic choriomeningitis virus infection in mice lacking serglycin. J. Immunol. 181: 1043-1051.
21. Meen, A. J., I. Øynebråten, T. M. Reine, A. Duelli, K. Svennevig, G. Pejler, T. Jenssen, and S. O. Kolset. 2011. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1. J. Biol. Chem. 286: 2636-2647.
22. Woulfe, D. S., J. K. Lilliendahl, S. August, L. Rauova, M. A. Kowalska, M. Abrink, G. Pejler, J. G. White, and B. P. Schick. 2008. Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood 111: 3458-3467.
23. Niemann, C. U., J. B. Cowland, P. Klausen, J. Askaa, J. Calafat, and N. Borregaard. 2004. Localization of serglycin in human neutrophil granulocytes and their precursors. J. Leukoc. Biol. 76: 406-415. (Pubitemid 39006955)
24. Niemann, C. U., M. Abrink, G. Pejler, R. L. Fischer, E. I. Christensen, S. D. Knight, and N. Borregaard. 2007. Neutrophil elastase depends on serglycin proteoglycan for localization in granules. Blood 109: 4478-4486. (Pubitemid 46743418)
25. Rothenberg, M. E., J. L. Pomerantz, W. F. Owen, Jr., S. Avraham, R. J. Soberman, K. F. Austen, and R. L. Stevens. 1988. Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J. Biol. Chem. 263: 13901-13908.
26. Zernichow, L., M. Abrink, J. Hallgren, M. Grujic, G. Pejler, and S. O. Kolset. 2006. Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-alpha secretion in response to lipopolysaccharide. J. Biol. Chem. 281: 26792-26801. (Pubitemid 44401708)
27. Theocharis, A. D., C. Seidel, M. Borset, K. Dobra, V. Baykov, V. Labropoulou, I. Kanakis, E. Dalas, N. K. Karamanos, A. Sundan, and A. Hjerpe. 2006. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J. Biol. Chem. 281: 35116-35128. (Pubitemid 46036551)
28. Li, X. J., C. K. Ong, Y. Cao, Y. Q. Xiang, J. Y. Shao, A. Ooi, L. X. Peng, W. H. Lu, Z. Zhang, D. Petillo, et al. 2011. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 71: 3162-3172.
29. Kolset, S. O., and J. T. Gallagher. 1990. Proteoglycans in haemopoietic cells. Biochim. Biophys. Acta 1032: 191-211. (Pubitemid 120036338)
30. Enerbäck, L., S. O. Kolset, M. Kusche, A. Hjerpe, and U. Lindahl. 1985. Glycosaminoglycans in rat mucosal mast cells. Biochem. J. 227: 661-668. (Pubitemid 15067741)
31. Stevens, R. L., T. D. Lee, D. C. Seldin, K. F. Austen, A. D. Befus, and J. Bienenstock. 1986. Intestinal mucosal mast cells from rats infected with Nippostrongylus brasiliensis contain protease-resistant chondroitin sulfate di-B proteoglycans. J. Immunol. 137: 291-295. (Pubitemid 16100302)
32. Lidholt, K., I. Eriksson, and L. Kjellén. 1995. Heparin proteoglycans synthesized by mouse mastocytoma contain chondroitin sulphate. Biochem. J. 311: 233-238.
33. Schick, B. P., T. I. Pestina, J. D. San Antonio, P. E. Stenberg, and C. W. Jackson. 1997. Decreased serglycin proteoglycan size is associated with the platelet alpha granule storage defect in Wistar Furth hereditary macrothrombocytopenic rats. Serglycin binding affinity to type I collagen is unaltered. J. Cell. Physiol. 172: 87-93. (Pubitemid 27283351)
34. Schmidt, R. E., R. P. MacDermott, G. Bartley, M. Bertovich, D. A. Amato, K. F. Austen, S. F. Schlossman, R. L. Stevens, and J. Ritz. 1985. Specific release of proteoglycans from human natural killer cells during target lysis. Nature 318: 289-291. (Pubitemid 16206731)
35. Zhang, L., M. Yang, D. Yang, G. Cavey, P. Davidson, and G. Gibson. 2010. Molecular interactions of MMP-13 C-terminal domain with chondrocyte proteins. Connect. Tissue Res. 51: 230-239.
36. Lemire, J. M., C. K. Chan, S. Bressler, J. Miller, R. G. LeBaron, and T. N. Wight. 2007. Interleukin-1beta selectively decreases the synthesis of versican by arterial smooth muscle cells. J. Cell. Biochem. 101: 753-766. (Pubitemid 46698859)
37. Toyama-Sorimachi, N., F. Kitamura, H. Habuchi, Y. Tobita, K. Kimata, and M. Miyasaka. 1997. Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells. J. Biol. Chem. 272: 26714-26719. (Pubitemid 27458898)
38. Niemann, C. U., L. Kjeldsen, E. Ralfkiaer, M. K. Jensen, and N. Borregaard. 2007. Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia 21: 2406-2410. (Pubitemid 350148881)
39. Niemann, C. U., J. B. Cowland, E. Ralfkiaer, M. Abrink, G. Pejler, and N. Borregaard. 2009. Serglycin proteoglycan is not implicated in localizing exocrine pancreas enzymes to zymogen granules. Eur. J. Cell Biol. 88: 473-479.
40. Avraham, S., K. F. Austen, C. F. Nicodemus, M. C. Gartner, and R. L. Stevens. 1989. Cloning and characterization of the mouse gene that encodes the peptide core of secretory granule proteoglycans and expression of this gene in transfected rat-1 fibroblasts. J. Biol. Chem. 264: 16719-16726. (Pubitemid 19243568)
41. Duelli, A., E. Rönnberg, I. Waern, M. Ringvall, S. O. Kolset, and G. Pejler. 2009. Mast cell differentiation and activation is closely linked to expression of genes coding for the serglycin proteoglycan core protein and a distinct set of chondroitin sulfate and heparin sulfotransferases. J. Immunol. 183: 7073-7083.
42. Schick, B. P., I. Petrushina, K. C. Brodbeck, and P. Castronuevo. 2001. Promoter regulatory elements and DNase I-hypersensitive sites involved in serglycin proteoglycan gene expression in human erythroleukemia, CHRF 288-11, and HL-60 cells. J. Biol. Chem. 276: 24726-24735.
43. Stellrecht, C. M., G. Fraizer, C. Selvanayagam, L. Y. Chao, A. Lee, and G. F. Saunders. 1993. Transcriptional regulation of a hematopoietic proteoglycan core protein gene during hematopoiesis. J. Biol. Chem. 268: 4078-4084. (Pubitemid 23072944)
44. Maillet, P., P. M. Alliel, M. T. Mitjavila, J. P. Périn, P. Jollès, and F. Bonnet. 1992. Expression of the serglycin gene in human leukemic cell lines. Leukemia 6: 1143-1147.
45. Stellrecht, C. M., W. M. Mars, H. Miwa, M. Beran, and G. F. Saunders. 1991. Expression pattern of a hematopoietic proteoglycan core protein gene during human hematopoiesis. Differentiation 48: 127-135.
46. Avraham, S., H. Avraham, K. F. Austen, and R. L. Stevens. 1992. Negative and positive cis-acting elements in the promoter of the mouse gene that encodes the serine/glycine-rich peptide core of secretory granule proteoglycans. J. Biol. Chem. 267: 610-617.
47. Castronuevo, P., M. A. Thornton, L. E. McCarthy, J. Klimas, and B. P. Schick. 2003. DNase I hypersensitivity patterns of the serglycin proteoglycan gene in resting and phorbol 12-myristate 13-acetate-stimulated human erythroleukemia (HEL), CHRF 288-11, and HL-60 cells compared with neutrophils and human umbilical vein endothelial cells. J. Biol. Chem. 278: 48704-48712. (Pubitemid 41079511)
48. Stevens, R. L., C. C. Fox, L. M. Lichtenstein, and K. F. Austen. 1988. Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc. Natl. Acad. Sci. USA 85: 2284-2287. (Pubitemid 24315875)
49. Forsberg, E., G. Pejler, M. Ringvall, C. Lunderius, B. Tomasini-Johansson, M. Kusche-Gullberg, I. Eriksson, J. Ledin, L. Hellman, and L. Kjellén. 1999. Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 400: 773-776. (Pubitemid 29399539)
50. Humphries, D. E., G. W. Wong, D. S. Friend, M. F. Gurish, W. T. Qiu, C. Huang, A. H. Sharpe, and R. L. Stevens. 1999. Heparin is essential for the storage of specific granule proteases in mast cells. Nature 400: 769-772. (Pubitemid 29399538)
51. Cowland, J. B., and N. Borregaard. 1999. The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J. Leukoc. Biol. 66: 989-995. (Pubitemid 30010525)
52. Henningsson, F., S. Hergeth, R. Cortelius, M. Abrink, and G. Pejler. 2006. A role for serglycin proteoglycan in granular retention and processing of mast cell secretory granule components. FEBS J. 273: 4901-4912. (Pubitemid 44583514)
53. Schick, B. P., J. F. Gradowski, and J. D. San Antonio. 2001. Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97: 449-458. (Pubitemid 32060330)
54. Pejler, G., and J. E. Sadler. 1999. Mechanism by which heparin proteoglycan modulates mast cell chymase activity. Biochemistry 38: 12187-12195.
55. Kunder, C. A., A. L. St John, G. Li, K. W. Leong, B. Berwin, H. F. Staats, and S. N. Abraham. 2009. Mast cell-derived particles deliver peripheral signals to remote lymph nodes. J. Exp. Med. 206: 2455-2467.
56. Wagner, L., O. O. Yang, E. A. Garcia-Zepeda, Y. Ge, S. A. Kalams, B. D. Walker, M. S. Pasternack, and A. D. Luster. 1998. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 391: 908-911. (Pubitemid 28157670)
57. Raja, S. M., B. Wang, M. Dantuluri, U. R. Desai, B. Demeler, K. Spiegel, S. S. Metkar, and C. J. Froelich. 2002. Cytotoxic cell granule-mediated apoptosis. Characterization of the macromolecular complex of granzyme B with serglycin. J. Biol. Chem. 277: 49523-49530. (Pubitemid 36014390)
58. Sawesi, O., D. Spillmann, A. Lundén, S. Wernersson, and M. Åbrink. 2010. Serglycin-independent release of active mast cell proteases in response to Toxoplasma gondii infection. J. Biol. Chem. 285: 38005-38013.
59. Hagman, R., E. Rönnberg, and G. Pejler. 2009. Canine uterine bacterial infection induces upregulation of proteolysis-related genes and downregulation of homeobox and zinc finger factors. PLoS ONE 4: e8039.
60. Wernersson, S., T. Braga, O. Sawesi, I. Waern, K. E. Nilsson, G. Pejler, and M. Abrink. 2009. Age-related enlargement of lymphoid tissue and altered leukocyte composition in serglycin-deficient mice. J. Leukoc. Biol. 85: 401-408.
61. Skliris, A., K. E. Happonen, E. Terpos, V. Labropoulou, M. Børset, D. Heinegård, A. M. Blom, and A. D. Theocharis. 2011. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur. J. Immunol. 41: 437-449.
62. Kirschfink, M., L. Blase, S. Engelmann, and R. Schwartz-Albiez. 1997. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1. J. Immunol. 158: 1324-1331. (Pubitemid 127469958)
63. Oschatz, C., C. Maas, B. Lecher, T. Jansen, J. Björkqvist, T. Tradler, R. Sedlmeier, P. Burfeind, S. Cichon, S. Hammerschmidt, et al. 2011. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34: 258-268.